Recon: FTC expresses concern over Novo Nordisk’s desire to buy Metsera; FDA OKs Caplyta as a add-on depression treatment

ReconReconAsiaBiotechnologyCanadaDiagnostics/IVDsEuropeMedical DevicesNutritional/Natural HealthPharmaceuticalsUnited States